All stock lists
Jin Medical International Ltd. (NASDAQ:ZJYL)
CN · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
2.35+0.49 (+26.34%)
Market cap
$18.4M
Insider Score
Health Score
Listed since
Mar 28, 2023
Website
Insider Score
––Not scored
ZJYL Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From ZJYL’s reported statements · Q1 2026 (trailing 12 months)
Profitability13 / 20
Profitable, but on a thin margin.
- Revenue
- $42.6M
- Net income
- $3.0M
- Net margin
- 7.0%
Leverage1 / 20
Heavily indebted for what it earns.
- Total debt
- $20.6M
- Cash
- $9.1M
- Net debt / EBITDA
- 3.80x
Liquidity19 / 20
Comfortably covers what is due within a year.
- Current assets
- $44.4M
- Current liabilities
- $22.8M
- Current ratio
- 1.95
Cash generation1 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- $712K
- Free cash flow
- -$7.8M
- FCF margin
- -18.3%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 7.8M
- Share growth (1y)
- 0.1%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ZJYL Income Statement
| Fiscal Period | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|
| Period Ending | Mar 31, 2026 | Sep 30, 2025 | Mar 30, 2025 | Sep 30, 2024 | Mar 30, 2024 | Sep 30, 2023 |
| Revenue | 8.92 M | 10.81 M | 9.88 M | 12.95 M | 10.56 M | 9.57 M |
| Revenue Growth (YoY) | -15.51 % | 12.93 % | -3.62 % | 33.14 % | 11.51 % | -15.68 % |
| Cost of Revenue | 6.52 M | 7.16 M | 7.35 M | 7.13 M | 6.76 M | 6.31 M |
| Gross Profit | 2.40 M | 3.64 M | 2.53 M | 5.81 M | 3.80 M | 3.25 M |
| SG&A Expense | 2.16 M | 1.68 M | 2.20 M | 2.47 M | 1.90 M | 1.25 M |
| R&D Expense | 881.73 K | 896.82 K | 660.89 K | 887.68 K | 609.65 K | 911.86 K |
| Operating Expenses | 3.04 M | 2.58 M | 2.99 M | 3.40 M | 2.57 M | 2.16 M |
| Operating Income | -644.45 K | 1.06 M | -454.21 K | 2.41 M | 1.23 M | 1.10 M |
| Pretax Income | -305.05 K | 1.57 M | 28.56 K | 2.17 M | 2.01 M | 1.25 M |
| Tax Provision | -96.04 K | 195.01 K | 19.57 K | 454.87 K | 309.01 K | 139.65 K |
| Net Income | -107.73 K | 1.28 M | -89.01 K | 1.88 M | 1.79 M | 1.11 M |
| EPS (Basic) | -0.01 | 0.16 | -0.01 | 0.24 | 0.23 | 0.14 |
| EPS (Diluted) | -0.01 | 0.16 | -0.01 | 0.24 | 0.23 | 0.14 |
| Shares Outstanding | 7.83 M | 7.83 M | 7.83 M | 7.83 M | 7.82 M | 7.80 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.